In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Cardiac dysfunction and athlete’s heart: new insights into pathophysiology and treatment

High-intensity exercise training may cause heart adaptations which compensate for increases in blood pressure or volume by increasing muscle mass. Physiological cardiac hypertrophy is associated with normal or enhanced cardiac function, but recent studies have documented decrements, especially in right ventricular (RV) function, during intense exercise and the release of cardiac damage markers in athlete’s blood of uncertain significance. Athlete’s heart is a physiological condition and does not require a specific treatment. The efficacy and the consequences on athletic performance of the common cardiovascular drugs are not well documented.

Heart Failure (HF)


Introduction

High-intensity exercise training leads to structural, functional, and electrical changes of the heart, which are referred to as ‘‘athlete’s heart’’, characterised by increased left ventricular mass (LVM), cavity dimensions and wall thickness [1]. Athletes with left ventricular hypertrophy generally have a normal ejection fraction (EF) and no evidence of either systolic or diastolic dysfunction [2]. Recent studies have documented decrements, especially in right ventricular (RV) function, during intense endurance exercise [3,4]. Actual evidence suggests that there may be some overlap between physiological and pathological hypertrophy, such that a small amount of fibrosis may accompany cardiac remodelling associated with lifelong endurance training and then acts as a substrate for arrhythmias [5].

Myocyte damage during high-intensity exercise 

After intense exercise, acute increases in troponin (cTn) and B-type natriuretic peptide (BNP) have been detected in athletes [6]. These are specific markers of myocyte damage and strain, but none of these indicates a permanent injury. Potential mechanisms have been proposed to explain cTn elevations after prolonged or strenuous exercise, but actually the release of cTn by healthy individuals cannot be explained by any of these theories. It is possible that exercise induces an increase in myocardial sarcolemma permeability with passive diffusion of cTn from the intracellular to extracellular compartment. The increase of membrane permeability might be due to mechanical stress on the cardiomyocytes, increased production of oxidative radicals or exercise-induced altered acid-base balance [6].

Some individuals with post-exercise cTn elevation might have myocardial injury with necrosis, taking into account the case reports of myocardial fibrosis and late gadolinium enhancement (LGE) in a small number of veteran athletes, but the pathogenesis of these cases remains unclear. However, routine cTn testing is not indicated for the evaluation of individuals who present for medical attention after participation in exercise sessions, unless there are specific clinical data suggesting cardiac involvement [6].

Key point:

  • Routine cTn and BNP testing is not indicated for the evaluation of athletes who present for medical attention after exercise sessions, unless there are specific clinical data suggesting cardiac involvement.

Exercise-related myocardial fibrosis

Despite the widely recognised benefits of regular physical activity, numerous observational studies have shown that high-level exercise training may be associated with an increased risk of cardiac arrhythmia and even primary cardiac arrest [7].

Athlete’s heart is a benign condition that represents a physiological adaptation to chronic training in which, usually, loss of myocytes and abnormal deposition of collagen do not occur. The fibrillar collagen network provides structural integrity of adjoining myocytes, facilitating myocyte shortening which translates into efficient cardiac pump function [8]. Pathological hypertrophy is associated with cell death (apoptosis, necrosis) and the loss of myocytes is replaced with excessive collagen. An excessive accumulation of collagen stiffens the ventricles, which impairs contraction and relaxation, damages the electrical coupling of cardiac myocytes with extracellular matrix proteins, and reduces capillary density. Fibrosis and reduced capillary density increase oxygen diffusion distances, leading to myocardial ischaemia. This is likely to contribute to the transition from hypertrophy to failure (Figure 1) [8]. Interestingly, recent studies have shown myocardial inflammation and fibrosis in animal models of long-term, intensive exercise. Chen et al [9] forced rats to swim strenuously, with histological evidence of localised myocyte damage, myocardial necrosis and inflammatory infiltrates. Benito et al [10] instituted an intensive treadmill running regime in young rats and showed that in the “marathon rats” there was an increase in atrial and ventricular inflammation/fibrosis. Most importantly, this was associated with a greater potential for inducible ventricular arrhythmias.

 

v14_36__Figure 1-v2.jpg

Figure 1. The different morphological and molecular characteristics between physiological remodelling (athlete’s heart) vs. pathological remodelling.

Fibrosis and inflammatory infiltrates have been identified in well-trained athletes who underwent a cardiac biopsy for high pre-test probability of identifying a cardiac pathology [11]. Histology provides the only direct evidence of fibrosis but, most commonly, inflammatory infiltrates and fibrosis are non-specific and their aetiology can be deduced only by other clinical factors. Furthermore, a cardiac biopsy is an invasive procedure with significant risks; it is not applicable in the absence of a strong suspicion of heart disease.

An accurate, non-invasive surrogate tool for detecting fibrosis is cardiac magnetic resonance (CMR) imaging with gadolinium contrast. Gadolinium-based extracellular paramagnetic contrast agents accumulate in areas of extracellular expansion and thus can be used to delineate areas of injured myocardium. Typically, areas of gadolinium accumulation relate to areas of scar expansion due to focal myocardial replacement fibrosis. Using gradient-echo inversion recovery imaging, fibrosis appears as a bright signal, with a prolonged wash-out time for the gadolinium (delayed gadolinium enhancement [DGE]), contrasting with the normal myocardium, which looks black [5]. Several studies have identified DGE in extensively trained veteran athletes. In most cases, the patches of DGE were very small and sited around the septum and RV insertion points, regions subjected to local mechanical stresses during exercise [5].

More recently, La Gerche et al have shown myocardial fibrosis with CMR, and a reduction in RV function occurred in those athletes competing for a longer duration, suggesting that the heart has a finite capacity to maintain the increased work demands of exercise. The patches of cardiac fibrosis may be the substrate for ventricular tachycardia and sudden death in predisposed individuals [3]. Based on this finding, some authors have recently proposed a new type of cardiomyopathy, the so-called Phidippides cardiomyopathy: repetitive sustained exertion can induce dilation of the cardiac chambers and also stimulates resident macrophages, pericytes, and fibroblasts, resulting in the deposition of collagen-causing patchy fibrosis [12,13]. CMR can also specifically detect intramyocardial fibro-fatty infiltration of the RV wall, typical of arrhythmogenic right ventricular cardiomyopathy (ARVC). This often leads to ventricular arrhythmias and usually appears in young adulthood, and in affected asymptomatic or minimally symptomatic individuals [13].

In conclusion, it is possible that the right ventricle is more susceptible to fatigue than the left ventricle (LV) after prolonged exercise. More studies are required to identify probable effects of exercise “dose” and their implication in the development of heart failure. Furthermore, it is important to underline that some banned athletic performance-enhancing drugs might have cardiac toxic effects, such as anabolic-androgenic steroids (AAS). Healthy athletes, abusing AAS, may exhibit LV hypertrophy with impairment of both systolic and diastolic myocardial function and focal areas of DGE, with a pattern of non-ischaemic distribution [14].

Figure 2 presents an algorithm for the differential diagnosis between an athlete’s heart and pathologic conditions. 

V14_36_Figure 2.jpg

Figure 2. Heart failure and athlete’s heart: a flow chart for a differential diagnosis.

Key points:

  • It is possible that the right ventricle is more susceptible to fatigue than the left ventricle after prolonged exercise.
  • Recent studies have shown fibrosis in athletes competing for a longer duration, sited around the septum and RV insertion points, regions subjected to local mechanical stresses during exercise.
  • The existence of Phidippides cardiomyopathy is uncertain.

Cardiovascular drugs in athletes

Athlete’s heart is a physiological condition and does not require a specific treatment. The athletic population and professional athletes are not risk free in terms of developing cardiovascular disease, despite the fact that regular exercise is a healthy habit and commonly protects against cardiac injury. Although the prevalence of high blood pressure (BP) is approximately 50% lower in athletes compared with the general population, it is also the most common cardiovascular condition in athletes. Therapy in this population can be difficult because of competition regulations and the potential adverse effects. Hypertension is associated with an increased risk of developing heart failure (HF); antihypertensive therapy markedly reduces the incidence of HF [15]. Unfortunately, few studies have evaluated the effects of antihypertensives in athletes and their consequences on exercise performance (Table 1) [16].

 

 Drug

 Side effects

Effects on exercise

 Diuretics

Dehydration

Electrolyte abnormalities

“Masking agents” for doping substances.

Diuretics are prohibited in competitive athletes.

α-blockers

Dizziness

Orthostatic hypotension

Nasal congestion

Headache

Fluid retention

Reflex tachycardia

No change in energy metabolism.

No change in VO2 max.

CCBs

Headache

Constipation

Fluid retention

Drowsiness

Hypotension

Dizziness

Minimal effect on exercise heart rate and VO2 max.

Dihydropyridines or long-acting diltiazem-like CCBs are well tolerated and effective in athletes.

ACEi

Cough and rash

Headache

Drowsiness

Weakness

 

No effects on heart rate and minimal effects on VO2 max.

First choice in athletes.

β-blockers

Fatigue

Cold hands

Headache

Constipation

Dizziness

Trouble sleeping

Loss of sex drive/erectile dysfunction

Depression

Important effects on heart rate and on VO2 max.

They are avoided in athletes.

CCBs: calcium channel blockers; ACEi: angiotensin-converting enzyme inhibitors.

Table 1. The side effects and the consequences on exercise of the most common cardiovascular drugs.

Diuretics are restricted in athletes, because their use may result in dehydration and electrolyte abnormalities, such as hypokalaemia. In addition, diuretics are prohibited in this population by the National Collegiate Athletic Association (NCAA) and the World Anti-Doping Agency (WADA), because they can be regarded as "masking" agents due to the dilution of urine, which results in lower levels of doping substances being excreted from the body [17].

Alpha-blocker drugs, blocking the effect of sympathetic nerves on blood vessels by binding to α-adrenoceptors located on the vascular smooth muscle, do not cause major changes in energy metabolism during exercise, and maximum oxygen uptake (VO2 max) is preserved. However, they are not widely used in athletes, given the associated side effects such as dizziness, orthostatic hypotension, nasal congestion, headache, fluid retention, and reflex tachycardia [18].

Beta-blockers in general have an adverse effect on exercise heart rate, VO2 max, when compared with placebo, and they are avoided in athletes [18,19].

Calcium channel blockers (CCBs) appear to have a minimal effect on exercise heart rate and VO2 max. Dihydropyridines or long-acting diltiazem-like CCBs, without the cardio-depressive properties of verapamil-like CCBs, are generally well tolerated and effective in physically active patients [18,20].

Angiotensin-converting enzyme inhibitors (ACEi) appear to be ideal agents for antihypertensive therapy in athletes. Several small studies have shown evidence that ACEi  have no effect on exercise heart rate and a minimal effect on VO2 max, and are well tolerated [18]. Unfortunately, data regarding ACEi and their action on athletes are lacking. The activation of the renin-angiotensin-aldosterone system is responsible for pathological cardiac hypertrophy and fibrosis, whereas in physiologic hypertrophy there is activation of the IGF1-PI3K-AKT1 pathway that protects the heart against failure, fibrosis and apoptosis, and inhibits the pathological signalling cascade. Therefore, the induction of physiological cardiac hypertrophy may be a potential therapeutic strategy for the treatment of heart failure [8].

Key points:

  • Data regarding the treatment of hypertension and the effects of cardiovascular drugs on exercise are lacking.
  • The first-line drugs in athletes for the treatment of hypertension are ACEì. They are well tolerated and have no effect on exercise.

Conclusions

The exact clinical significance and prognostic value of cardiac injury and fibrosis in athletes are unknown. More large prospective studies are needed to provide a better understanding of these conditions and to investigate the effects of cardiovascular drugs in this population.

References


  1. La Gerche A, Taylor AJ, Prior DL. Athlete's heart: the potential for multimodality imaging to address the critical remaining questions. JACC Cardiovasc Imaging. 2009 Mar;2(3):350-63.
  2. Lazzeroni D, Rimoldi O, Camici PG. From Left Ventricular Hypertrophy to Dysfunction and Failure. Circ J. 2016;80(3):555-64.
  3. La Gerche A, Burns AT, Mooney DJ, Inder WJ, Taylor AJ, Bogaert J, Macisaac AI, Heidbüchel H. Prior DL. Exercise-induced right ventricular dysfunction and structural remodelling in endurance athletes. Eur Heart J. 2012 Apr;33(8):998-1006.
  4. D'Andrea A, La Gerche A, Golia E, Padalino R, Calabrò R, Russo MG, Bossone E. Physiologic and pathophysiologic changes in the right heart in highly trained athletes. Herz. 2015 May;40(3):369-78.
  5. La Gerche A. Can intense endurance exercise cause myocardial damage and fibrosis? Curr Sports Med Rep. 2013 Mar-Apr;12(2):63-9.
  6. Shave R, Baggish A, George K, Wood M, Scharhag J, Whyte G, Gaze D, Thompson PD. Exercise-induced cardiac troponin elevation: evidence, mechanisms, and implications. J Am Coll Cardiol. 2010 Jul 13;56(3):169-76.
  7. Siscovick DS, Weiss NS, Fletcher RH, Lasky T. The incidence of primary cardiac arrest during vigorous exercise. N Engl J Med. 1984 Oct 4;311(14):874-7.
  8. Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther. 2010 Oct;128(1):191-227.
  9. Chen Y, Serfass RC, Mackey-Bojack SM, Kelly KL, Titus JL, Apple FS. Cardiac troponin T alterations in myocardium and serum of rats after stressful, prolonged intense exercise. J Appl Physiol (1985). 2000 May;88(5):1749-55.
  10. Benito B, Gay-Jordi G, Serrano-Mollar A, Guasch E, Shi Y, Tardif JC, Brugada J, Nattel S, Mont L. Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training. Circulation. 2011 Jan 4;123(1):13-22.
  11. Dello Russo A, Pieroni M, Santangeli P, Bartoletti S, Casella M, Pelargonio G, Smaldone C, Bianco M, Di Biase L, Bellocci F, Zeppilli P, Fiorentini C, Natale A, Tondo C. Concealed cardiomyopathies in competitive athletes with ventricular arrhythmias and an apparently normal heart: role of cardiac electroanatomical mapping and biopsy. Heart Rhythm. 2011 Dec;8(12):1915-22.
  12. Trivax JE, McCullough PA. Phidippides cardiomyopathy: a review and case illustration. Clin Cardiol. 2012 Feb;35(2):69-73.
  13. Limongelli G, Rea A, Masarone D, Francalanci MP, Anastasakis A, Calabro' R, Giovanna RM, Bossone E, Elliott PM, Pacileo G. Right ventricular cardiomyopathies: a multidisciplinary approach to diagnosis. Echocardiography. 2015 Jan;32 Suppl 1:S75-94.
  14. D'Andrea A, Limongelli G, Morello A, Mattera Iacono A, Russo MG, Bossone E, Calabrò R, Pacileo G. Anabolic-androgenic steroids and athlete's heart: When big is not beautiful....! Int J Cardiol. 2016 Jan 15;203:486-8.
  15. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-200.
  16. Oliveira LP, Lawless CE. Hypertension update and cardiovascular risk reduction in physically active individuals and athletes. Phys Sportsmed. 2010 Apr;38(1):11-20.
  17. Estes NA 3rd, Kovacs RJ, Baggish AL, Myerburg RJ; American Heart Association Electrocardiography and Arrhythmias Committee of Council on Clinical Cardiology, Council on Cardiovascular Disease in Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and American College of Cardiology. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 11: Drugs and Performance-Enhancing Substances: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation. 2015 Dec 1;132(22):e330-3.  
  18. Asplund C. Treatment of hypertension in athletes: an evidence-based review. Phys Sportsmed. 2010 Apr;38(1):37-44.
  19. Carre F, Handschuh R, Beillot J, Dassonville J, Rochcongar P, Guivarc'h PH, Lessard Y. Effects of captopril chronic intake on the aerobic performance and muscle strength of normotensive trained subjects. Int J Sports Med. 1992 May;13(4):308-12.
  20. Pool PE, Seagren SC, Salel AF. Effects of diltiazem on serum lipids, exercise performance and blood pressure: randomized, double-blind, placebo-controlled evaluation for systemic hypertension. Am J Cardiol. 1985 Dec;56(16):86H-91H.

Notes to editor


Authors:

Andreina Carbone, MD; Antonello D’Andrea, MD, PhD, FESC

Department of Cardiology, Second University of Naples, Monaldi Hospital, Naples, Italy

 

Author for correspondence:

Dr. Andreina Carbone,

Via Guglielmo Marconi, 15,

80010 Villaricca (NA),

Italy

E-mail: andr.carbone@gmail.com

 

Author disclosures:

The authors have no conflicts of interest to declare.

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.